BrightGene Bio-Medical Technology Co., Ltd. (SHA:688166)

China flag China · Delayed Price · Currency is CNY
40.92
+0.65 (1.61%)
At close: Mar 6, 2026
15.79%
Market Cap 17.30B
Revenue (ttm) 1.22B
Net Income (ttm) 56.06M
Shares Out 422.74M
EPS (ttm) 0.13
PE Ratio 308.59
Forward PE n/a
Dividend 0.10 (0.23%)
Ex-Dividend Date Jun 23, 2025
Volume 9,912,248
Average Volume 7,302,891
Open 40.22
Previous Close 40.27
Day's Range 40.05 - 41.65
52-Week Range 32.01 - 122.59
Beta 0.17
RSI 30.67
Earnings Date Mar 20, 2026

About SHA:688166

BrightGene Bio-Medical Technology Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in China and internationally. The company develops BGM0504 injection, which is in Phase III clinical trial for treatment of type 2 diabetes and weight loss; and BGM1812, a long-acting amylin analog in preclinical development. It also provides formulations; preparation products; active pharmaceutical ingredients and intermediates; and veterinary drugs for various therapeutic areas, inc... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 1,162
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688166
Full Company Profile

Financial Performance

In 2025, SHA:688166's revenue was 1.22 billion, a decrease of -4.59% compared to the previous year's 1.28 billion. Earnings were 56.06 million, a decrease of -70.37%.

Financial Statements

News

There is no news available yet.